ID   ITK_HUMAN               Reviewed;         620 AA.
AC   Q08881; B2R752; Q32ML7;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1994, sequence version 1.
DT   12-OCT-2022, entry version 223.
DE   RecName: Full=Tyrosine-protein kinase ITK/TSK;
DE            EC=2.7.10.2;
DE   AltName: Full=Interleukin-2-inducible T-cell kinase;
DE            Short=IL-2-inducible T-cell kinase;
DE   AltName: Full=Kinase EMT;
DE   AltName: Full=T-cell-specific kinase;
DE   AltName: Full=Tyrosine-protein kinase Lyk;
GN   Name=ITK; Synonyms=EMT, LYK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INDUCTION.
RX   PubMed=8504851; DOI=10.1016/0014-5793(93)81520-a;
RA   Tanaka N., Asao H., Ohtani K., Nakamura M., Sugamura K.;
RT   "A novel human tyrosine kinase gene inducible in T cells by interleukin
RT   2.";
RL   FEBS Lett. 324:1-5(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Thymus;
RX   PubMed=8364206;
RA   Gibson S., Leung B., Squire J.A., Hill M., Arima N., Goss P., Hogg D.,
RA   Mills G.B.;
RT   "Identification, cloning, and characterization of a novel human T-cell-
RT   specific tyrosine kinase located at the hematopoietin complex on chromosome
RT   5q.";
RL   Blood 82:1561-1572(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 171-192, AND PHOSPHORYLATION AT TYR-180.
RX   PubMed=12573241; DOI=10.1016/s1570-9639(02)00524-1;
RA   Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A.,
RA   Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.;
RT   "Identification of phosphorylation sites within the SH3 domains of Tec
RT   family tyrosine kinases.";
RL   Biochim. Biophys. Acta 1645:123-132(2003).
RN   [7]
RP   PHOSPHORYLATION BY LCK.
RX   PubMed=9312162; DOI=10.1074/jbc.272.40.25401;
RA   Heyeck S.D., Wilcox H.M., Bunnell S.C., Berg L.J.;
RT   "Lck phosphorylates the activation loop tyrosine of the Itk kinase domain
RT   and activates Itk kinase activity.";
RL   J. Biol. Chem. 272:25401-25408(1997).
RN   [8]
RP   INDUCTION.
RX   PubMed=9701039; DOI=10.1093/intimm/10.7.1009;
RA   King P.D., Sadra A., Teng J.M., Bell G.M., Dupont B.;
RT   "CD2-mediated activation of the Tec-family tyrosine kinase ITK is
RT   controlled by proline-rich stretch-4 of the CD2 cytoplasmic tail.";
RL   Int. Immunol. 10:1009-1016(1998).
RN   [9]
RP   DOMAIN.
RX   PubMed=10795735; DOI=10.1016/s1074-7613(00)80189-2;
RA   Yang W.C., Collette Y., Nunes J.A., Olive D.;
RT   "Tec kinases: a family with multiple roles in immunity.";
RL   Immunity 12:373-382(2000).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF LAT.
RX   PubMed=12186560; DOI=10.1021/bi025554o;
RA   Perez-Villar J.J., Whitney G.S., Sitnick M.T., Dunn R.J., Venkatesan S.,
RA   O'Day K., Schieven G.L., Lin T.A., Kanner S.B.;
RT   "Phosphorylation of the linker for activation of T-cells by Itk promotes
RT   recruitment of Vav.";
RL   Biochemistry 41:10732-10740(2002).
RN   [11]
RP   FUNCTION.
RX   PubMed=12682224; DOI=10.4049/jimmunol.170.8.3971;
RA   Grasis J.A., Browne C.D., Tsoukas C.D.;
RT   "Inducible T cell tyrosine kinase regulates actin-dependent cytoskeletal
RT   events induced by the T cell antigen receptor.";
RL   J. Immunol. 170:3971-3976(2003).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [13]
RP   INTERACTION WITH PPIA/CYPA, AND MUTAGENESIS OF PRO-288.
RX   PubMed=15308100; DOI=10.1016/j.immuni.2004.07.005;
RA   Colgan J., Asmal M., Neagu M., Yu B., Schneidkraut J., Lee Y.,
RA   Sokolskaja E., Andreotti A., Luban J.;
RT   "Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline-
RT   directed conformational switch in Itk.";
RL   Immunity 21:189-201(2004).
RN   [14]
RP   INTERACTION WITH VAV1.
RX   PubMed=15661896; DOI=10.4049/jimmunol.174.3.1385;
RA   Dombroski D., Houghtling R.A., Labno C.M., Precht P., Takesono A.,
RA   Caplen N.J., Billadeau D.D., Wange R.L., Burkhardt J.K., Schwartzberg P.L.;
RT   "Kinase-independent functions for Itk in TCR-induced regulation of Vav and
RT   the actin cytoskeleton.";
RL   J. Immunol. 174:1385-1392(2005).
RN   [15]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17060314; DOI=10.1074/jbc.m609180200;
RA   Qi Q., Sahu N., August A.;
RT   "Tec kinase Itk forms membrane clusters specifically in the vicinity of
RT   recruiting receptors.";
RL   J. Biol. Chem. 281:38529-38534(2006).
RN   [16]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL (CD178) by
RT   phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [17]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=19523959; DOI=10.1016/j.jmb.2009.06.023;
RA   Joseph R.E., Severin A., Min L., Fulton D.B., Andreotti A.H.;
RT   "SH2-dependent autophosphorylation within the Tec family kinase Itk.";
RL   J. Mol. Biol. 391:164-177(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-512 AND SER-565, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   UBIQUITINATION.
RX   PubMed=20596523; DOI=10.1371/journal.pone.0011332;
RA   Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B.,
RA   Spruck C.;
RT   "Development and validation of a method for profiling post-translational
RT   modification activities using protein microarrays.";
RL   PLoS ONE 5:E11332-E11332(2010).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF LCP2.
RX   PubMed=21725281; DOI=10.1038/emboj.2011.213;
RA   Sela M., Bogin Y., Beach D., Oellerich T., Lehne J., Smith-Garvin J.E.,
RA   Okumura M., Starosvetsky E., Kosoff R., Libman E., Koretzky G.,
RA   Kambayashi T., Urlaub H., Wienands J., Chernoff J., Yablonski D.;
RT   "Sequential phosphorylation of SLP-76 at tyrosine 173 is required for
RT   activation of T and mast cells.";
RL   EMBO J. 30:3160-3172(2011).
RN   [21]
RP   STRUCTURE BY NMR OF 113-239.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the BTK motif and the SH3 domain of tyrosine-protein
RT   kinase ITK from human.";
RL   Submitted (OCT-2007) to the PDB data bank.
RN   [22]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-19; LEU-23; GLN-451; TRP-581 AND
RP   ILE-587.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [23]
RP   VARIANT LPFS1 TRP-335, AND CHARACTERIZATION OF VARIANT LPSA1 TRP-335.
RX   PubMed=19425169; DOI=10.1172/jci37901;
RA   Huck K., Feyen O., Niehues T., Rueschendorf F., Huebner N., Laws H.-J.,
RA   Telieps T., Knapp S., Wacker H.-H., Meindl A., Jumaa H., Borkhardt A.;
RT   "Girls homozygous for an IL-2-inducible T cell kinase mutation that leads
RT   to protein deficiency develop fatal EBV-associated lymphoproliferation.";
RL   J. Clin. Invest. 119:1350-1358(2009).
CC   -!- FUNCTION: Tyrosine kinase that plays an essential role in regulation of
CC       the adaptive immune response. Regulates the development, function and
CC       differentiation of conventional T-cells and nonconventional NKT-cells.
CC       When antigen presenting cells (APC) activate T-cell receptor (TCR), a
CC       series of phosphorylation lead to the recruitment of ITK to the cell
CC       membrane, in the vicinity of the stimulated TCR receptor, where it is
CC       phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation
CC       and full activation. Once activated, phosphorylates PLCG1, leading to
CC       the activation of this lipase and subsequent cleavage of its
CC       substrates. In turn, the endoplasmic reticulum releases calcium in the
CC       cytoplasm and the nuclear activator of activated T-cells (NFAT)
CC       translocates into the nucleus to perform its transcriptional duty.
CC       Phosphorylates 2 essential adapter proteins: the linker for activation
CC       of T-cells/LAT protein and LCP2. Then, a large number of signaling
CC       molecules such as VAV1 are recruited and ultimately lead to lymphokine
CC       production, T-cell proliferation and differentiation (PubMed:12186560,
CC       PubMed:12682224, PubMed:21725281). Required for TCR-mediated calcium
CC       response in gamma-delta T-cells, may also be involved in the modulation
CC       of the transcriptomic signature in the Vgamma2-positive subset of
CC       immature gamma-delta T-cells (By similarity). Phosphorylates TBX21 at
CC       'Tyr-530' and mediates its interaction with GATA3 (By similarity).
CC       {ECO:0000250|UniProtKB:Q03526, ECO:0000269|PubMed:12186560,
CC       ECO:0000269|PubMed:12682224, ECO:0000269|PubMed:21725281}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Homooligomerizes; this association negatively regulates kinase
CC       activity (By similarity). Interacts with PPIA/CYPA; this interaction
CC       regulates TCR signal strength via a proline-directed conformational
CC       switch in ITK. Interacts with THEMIS (By similarity). Interacts with
CC       FASLG. Interacts with VAV1; this interaction is important for VAV1
CC       localization and TCR-induced actin polarization. Interacts with TBX21
CC       (By similarity). {ECO:0000250|UniProtKB:Q03526,
CC       ECO:0000269|PubMed:15308100, ECO:0000269|PubMed:15661896,
CC       ECO:0000269|PubMed:19807924}.
CC   -!- INTERACTION:
CC       Q08881; P04626: ERBB2; NbExp=2; IntAct=EBI-968552, EBI-641062;
CC       Q08881; P48023: FASLG; NbExp=3; IntAct=EBI-968552, EBI-495538;
CC       Q08881; P08238: HSP90AB1; NbExp=3; IntAct=EBI-968552, EBI-352572;
CC       Q08881; Q13094: LCP2; NbExp=3; IntAct=EBI-968552, EBI-346946;
CC       Q08881; P10686: Plcg1; Xeno; NbExp=2; IntAct=EBI-968552, EBI-520788;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17060314}. Nucleus
CC       {ECO:0000250|UniProtKB:Q03526}. Note=Localizes in the vicinity of cell
CC       surface receptors in the plasma membrane after receptor stimulation.
CC   -!- TISSUE SPECIFICITY: T-cell lines and natural killer cell lines.
CC   -!- INDUCTION: Through a myriad of surface receptors including the TCR/CD3
CC       signaling complex, coreceptors, or chemokine receptors.
CC       {ECO:0000269|PubMed:8504851, ECO:0000269|PubMed:9701039}.
CC   -!- DOMAIN: The N-terminal PH domain allows ITK to be recruited to the
CC       plasma membrane by an activated PI3 kinase. This domain contains also a
CC       proline-rich region (PRR). The adjoining domain is a SH3 domain, which
CC       binds to PRR (from itself or from other proteins). Next, a SH2 domain
CC       is required for binding tyrosine-phosphorylated substrates. In the C-
CC       terminal region, the kinase domain is required for tyrosine
CC       phosphorylation. {ECO:0000269|PubMed:10795735}.
CC   -!- PTM: Phosphorylated at Tyr-512 in the activation loop of the kinase
CC       domain by LCK. Subsequent autophosphorylation at Tyr-180 leads to the
CC       kinase activation. The autophosphorylated Tyr-180 lies within the
CC       substrate binding sequence of the SH3 domain.
CC       {ECO:0000269|PubMed:12573241, ECO:0000269|PubMed:9312162}.
CC   -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:20596523}.
CC   -!- DISEASE: Lymphoproliferative syndrome 1 (LPFS1) [MIM:613011]: A rare
CC       immunodeficiency characterized by extreme susceptibility to infection
CC       with Epstein-Barr virus (EBV). Inadequate immune response to EBV can
CC       have a fatal outcome. Clinical features include splenomegaly,
CC       lymphadenopathy, anemia, thrombocytopenia, pancytopenia, recurrent
CC       infections. There is an increased risk for lymphoma.
CC       {ECO:0000269|PubMed:19425169}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. TEC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ITKID43329ch5q33.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D13720; BAA02873.1; -; mRNA.
DR   EMBL; L10717; AAA36748.1; -; mRNA.
DR   EMBL; S65186; AAB28072.2; -; mRNA.
DR   EMBL; AK312846; BAG35699.1; -; mRNA.
DR   EMBL; CH471062; EAW61608.1; -; Genomic_DNA.
DR   EMBL; BC109077; AAI09078.1; -; mRNA.
DR   EMBL; BC109078; AAI09079.1; -; mRNA.
DR   CCDS; CCDS4336.1; -.
DR   PIR; S33253; S33253.
DR   RefSeq; NP_005537.3; NM_005546.3.
DR   PDB; 1SM2; X-ray; 2.30 A; A/B=357-620.
DR   PDB; 1SNU; X-ray; 2.50 A; A/B=357-620.
DR   PDB; 1SNX; X-ray; 3.20 A; A/B=357-620.
DR   PDB; 2E6I; NMR; -; A=113-169.
DR   PDB; 2LMJ; NMR; -; A=171-231.
DR   PDB; 2YUQ; NMR; -; A=162-239.
DR   PDB; 3MIY; X-ray; 1.67 A; A/B=357-620.
DR   PDB; 3MJ1; X-ray; 1.72 A; A=357-620.
DR   PDB; 3MJ2; X-ray; 1.90 A; A=357-620.
DR   PDB; 3QGW; X-ray; 2.10 A; A/B=357-620.
DR   PDB; 3QGY; X-ray; 2.10 A; A/B=357-620.
DR   PDB; 3T9T; X-ray; 1.65 A; A=354-620.
DR   PDB; 3V5J; X-ray; 2.59 A; A/B=357-620.
DR   PDB; 3V5L; X-ray; 1.86 A; A/B/C/D=357-620.
DR   PDB; 3V8T; X-ray; 2.00 A; A/B=357-620.
DR   PDB; 3V8W; X-ray; 2.27 A; A/B=357-620.
DR   PDB; 4HCT; X-ray; 1.48 A; A=354-620.
DR   PDB; 4HCU; X-ray; 1.43 A; A=354-620.
DR   PDB; 4HCV; X-ray; 1.48 A; A=354-620.
DR   PDB; 4KIO; X-ray; 2.18 A; A/B/C/D=357-620.
DR   PDB; 4L7S; X-ray; 2.03 A; A/B=357-620.
DR   PDB; 4M0Y; X-ray; 1.70 A; A=354-620.
DR   PDB; 4M0Z; X-ray; 2.00 A; A=354-620.
DR   PDB; 4M12; X-ray; 2.15 A; A=354-620.
DR   PDB; 4M13; X-ray; 1.85 A; A=354-620.
DR   PDB; 4M14; X-ray; 1.55 A; A=354-620.
DR   PDB; 4M15; X-ray; 1.52 A; A=354-620.
DR   PDB; 4MF0; X-ray; 2.67 A; A/B=357-620.
DR   PDB; 4MF1; X-ray; 2.11 A; A/B=357-620.
DR   PDB; 4PP9; X-ray; 2.58 A; A/B=357-620.
DR   PDB; 4PPA; X-ray; 2.67 A; A/B=357-620.
DR   PDB; 4PPB; X-ray; 2.82 A; A/B=357-620.
DR   PDB; 4PPC; X-ray; 2.95 A; A/B=357-620.
DR   PDB; 4PQN; X-ray; 1.71 A; A=357-620.
DR   PDB; 4QD6; X-ray; 2.45 A; A/B=357-620.
DR   PDB; 4RFM; X-ray; 2.10 A; A=357-620.
DR   PDBsum; 1SM2; -.
DR   PDBsum; 1SNU; -.
DR   PDBsum; 1SNX; -.
DR   PDBsum; 2E6I; -.
DR   PDBsum; 2LMJ; -.
DR   PDBsum; 2YUQ; -.
DR   PDBsum; 3MIY; -.
DR   PDBsum; 3MJ1; -.
DR   PDBsum; 3MJ2; -.
DR   PDBsum; 3QGW; -.
DR   PDBsum; 3QGY; -.
DR   PDBsum; 3T9T; -.
DR   PDBsum; 3V5J; -.
DR   PDBsum; 3V5L; -.
DR   PDBsum; 3V8T; -.
DR   PDBsum; 3V8W; -.
DR   PDBsum; 4HCT; -.
DR   PDBsum; 4HCU; -.
DR   PDBsum; 4HCV; -.
DR   PDBsum; 4KIO; -.
DR   PDBsum; 4L7S; -.
DR   PDBsum; 4M0Y; -.
DR   PDBsum; 4M0Z; -.
DR   PDBsum; 4M12; -.
DR   PDBsum; 4M13; -.
DR   PDBsum; 4M14; -.
DR   PDBsum; 4M15; -.
DR   PDBsum; 4MF0; -.
DR   PDBsum; 4MF1; -.
DR   PDBsum; 4PP9; -.
DR   PDBsum; 4PPA; -.
DR   PDBsum; 4PPB; -.
DR   PDBsum; 4PPC; -.
DR   PDBsum; 4PQN; -.
DR   PDBsum; 4QD6; -.
DR   PDBsum; 4RFM; -.
DR   AlphaFoldDB; Q08881; -.
DR   BMRB; Q08881; -.
DR   SMR; Q08881; -.
DR   BioGRID; 109907; 45.
DR   CORUM; Q08881; -.
DR   DIP; DIP-29974N; -.
DR   IntAct; Q08881; 33.
DR   MINT; Q08881; -.
DR   STRING; 9606.ENSP00000398655; -.
DR   BindingDB; Q08881; -.
DR   ChEMBL; CHEMBL2959; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB02010; Staurosporine.
DR   DrugBank; DB15035; Zanubrutinib.
DR   DrugCentral; Q08881; -.
DR   GuidetoPHARMACOLOGY; 2046; -.
DR   iPTMnet; Q08881; -.
DR   PhosphoSitePlus; Q08881; -.
DR   BioMuta; ITK; -.
DR   DMDM; 585361; -.
DR   jPOST; Q08881; -.
DR   MassIVE; Q08881; -.
DR   MaxQB; Q08881; -.
DR   PaxDb; Q08881; -.
DR   PeptideAtlas; Q08881; -.
DR   PRIDE; Q08881; -.
DR   ProteomicsDB; 58650; -.
DR   ABCD; Q08881; 4 sequenced antibodies.
DR   Antibodypedia; 16533; 506 antibodies from 41 providers.
DR   DNASU; 3702; -.
DR   Ensembl; ENST00000422843.8; ENSP00000398655.4; ENSG00000113263.13.
DR   GeneID; 3702; -.
DR   KEGG; hsa:3702; -.
DR   MANE-Select; ENST00000422843.8; ENSP00000398655.4; NM_005546.4; NP_005537.3.
DR   UCSC; uc003lwo.2; human.
DR   CTD; 3702; -.
DR   DisGeNET; 3702; -.
DR   GeneCards; ITK; -.
DR   HGNC; HGNC:6171; ITK.
DR   HPA; ENSG00000113263; Tissue enriched (lymphoid).
DR   MalaCards; ITK; -.
DR   MIM; 186973; gene.
DR   MIM; 613011; phenotype.
DR   neXtProt; NX_Q08881; -.
DR   OpenTargets; ENSG00000113263; -.
DR   Orphanet; 538963; Combined immunodeficiency due to ITK deficiency.
DR   PharmGKB; PA29968; -.
DR   VEuPathDB; HostDB:ENSG00000113263; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   GeneTree; ENSGT00940000158850; -.
DR   HOGENOM; CLU_000288_7_2_1; -.
DR   InParanoid; Q08881; -.
DR   OMA; RMGKDER; -.
DR   OrthoDB; 1047190at2759; -.
DR   PhylomeDB; Q08881; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; Q08881; -.
DR   Reactome; R-HSA-202433; Generation of second messenger molecules.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   SignaLink; Q08881; -.
DR   SIGNOR; Q08881; -.
DR   BioGRID-ORCS; 3702; 14 hits in 1105 CRISPR screens.
DR   ChiTaRS; ITK; human.
DR   EvolutionaryTrace; Q08881; -.
DR   GeneWiki; ITK_(gene); -.
DR   GenomeRNAi; 3702; -.
DR   Pharos; Q08881; Tclin.
DR   PRO; PR:Q08881; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q08881; protein.
DR   Bgee; ENSG00000113263; Expressed in granulocyte and 128 other tissues.
DR   ExpressionAtlas; Q08881; baseline and differential.
DR   Genevisible; Q08881; HS.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0007202; P:activation of phospholipase C activity; ISS:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; ISS:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0006968; P:cellular defense response; TAS:ProtInc.
DR   GO; GO:0046629; P:gamma-delta T cell activation; ISS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0001865; P:NK T cell differentiation; IBA:GO_Central.
DR   GO; GO:0001819; P:positive regulation of cytokine production; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0042110; P:T cell activation; TAS:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; ISS:UniProtKB.
DR   CDD; cd05112; PTKc_Itk; 1.
DR   CDD; cd11908; SH3_ITK; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR042785; ITK_PTKc.
DR   InterPro; IPR035583; ITK_SH3.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001562; Znf_Btk_motif.
DR   Pfam; PF00779; BTK; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00107; BTK; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
DR   PROSITE; PS51113; ZF_BTK; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; ATP-binding; Cytoplasm;
KW   Direct protein sequencing; Disease variant; Immunity; Kinase;
KW   Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..620
FT                   /note="Tyrosine-protein kinase ITK/TSK"
FT                   /id="PRO_0000088106"
FT   DOMAIN          4..111
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          171..231
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          239..338
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          363..615
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ZN_FING         113..149
FT                   /note="Btk-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432"
FT   ACT_SITE        482
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         121
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432"
FT   BINDING         132
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432"
FT   BINDING         133
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432"
FT   BINDING         143
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432"
FT   BINDING         369..377
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         391
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         180
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12573241"
FT   MOD_RES         512
FT                   /note="Phosphotyrosine; by LCK"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         565
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   VARIANT         19
FT                   /note="R -> K (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041710"
FT   VARIANT         23
FT                   /note="P -> L (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041711"
FT   VARIANT         193
FT                   /note="R -> Q (in dbSNP:rs17054374)"
FT                   /id="VAR_051696"
FT   VARIANT         335
FT                   /note="R -> W (in LPFS1; shows nearly undetectable mutant
FT                   ITK protein consistent with severe protein instability;
FT                   dbSNP:rs121908191)"
FT                   /evidence="ECO:0000269|PubMed:19425169"
FT                   /id="VAR_063424"
FT   VARIANT         451
FT                   /note="R -> Q (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs779372373)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041712"
FT   VARIANT         581
FT                   /note="R -> W (in dbSNP:rs34482255)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041713"
FT   VARIANT         587
FT                   /note="V -> I (in dbSNP:rs56005928)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041714"
FT   MUTAGEN         288
FT                   /note="P->G: Complete loss of interaction with PPIA/CYPA."
FT                   /evidence="ECO:0000269|PubMed:15308100"
FT   CONFLICT        171..172
FT                   /note="PE -> GS (in Ref. 6; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        331
FT                   /note="V -> W (in Ref. 2; AAB28072)"
FT                   /evidence="ECO:0000305"
FT   STRAND          127..133
FT                   /evidence="ECO:0007829|PDB:2E6I"
FT   STRAND          148..152
FT                   /evidence="ECO:0007829|PDB:2E6I"
FT   STRAND          171..173
FT                   /evidence="ECO:0007829|PDB:2YUQ"
FT   STRAND          175..180
FT                   /evidence="ECO:0007829|PDB:2LMJ"
FT   STRAND          187..189
FT                   /evidence="ECO:0007829|PDB:2YUQ"
FT   STRAND          197..205
FT                   /evidence="ECO:0007829|PDB:2LMJ"
FT   STRAND          208..212
FT                   /evidence="ECO:0007829|PDB:2LMJ"
FT   STRAND          214..216
FT                   /evidence="ECO:0007829|PDB:2LMJ"
FT   STRAND          218..221
FT                   /evidence="ECO:0007829|PDB:2LMJ"
FT   HELIX           223..225
FT                   /evidence="ECO:0007829|PDB:2LMJ"
FT   STRAND          226..228
FT                   /evidence="ECO:0007829|PDB:2LMJ"
FT   HELIX           360..362
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   STRAND          363..371
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   STRAND          373..375
FT                   /evidence="ECO:0007829|PDB:4KIO"
FT   STRAND          376..382
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   TURN            383..385
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   STRAND          386..393
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   TURN            395..397
FT                   /evidence="ECO:0007829|PDB:3T9T"
FT   HELIX           400..411
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   STRAND          421..425
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   STRAND          427..436
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   HELIX           443..448
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   TURN            449..452
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   HELIX           456..475
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   HELIX           485..487
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   STRAND          488..490
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   HELIX           492..494
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   STRAND          496..498
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   HELIX           503..506
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   HELIX           510..513
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   HELIX           522..524
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   HELIX           527..532
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   HELIX           537..552
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   TURN            553..555
FT                   /evidence="ECO:0007829|PDB:4PQN"
FT   TURN            558..561
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   HELIX           564..572
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   STRAND          581..583
FT                   /evidence="ECO:0007829|PDB:3V8W"
FT   HELIX           585..594
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   HELIX           599..601
FT                   /evidence="ECO:0007829|PDB:4HCU"
FT   HELIX           605..617
FT                   /evidence="ECO:0007829|PDB:4HCU"
SQ   SEQUENCE   620 AA;  71831 MW;  DAE396BD2309319D CRC64;
     MNNFILLEEQ LIKKSQQKRR TSPSNFKVRF FVLTKASLAY FEDRHGKKRT LKGSIELSRI
     KCVEIVKSDI SIPCHYKYPF QVVHDNYLLY VFAPDRESRQ RWVLALKEET RNNNSLVPKY
     HPNFWMDGKW RCCSQLEKLA TGCAQYDPTK NASKKPLPPT PEDNRRPLWE PEETVVIALY
     DYQTNDPQEL ALRRNEEYCL LDSSEIHWWR VQDRNGHEGY VPSSYLVEKS PNNLETYEWY
     NKSISRDKAE KLLLDTGKEG AFMVRDSRTA GTYTVSVFTK AVVSENNPCI KHYHIKETND
     NPKRYYVAEK YVFDSIPLLI NYHQHNGGGL VTRLRYPVCF GRQKAPVTAG LRYGKWVIDP
     SELTFVQEIG SGQFGLVHLG YWLNKDKVAI KTIREGAMSE EDFIEEAEVM MKLSHPKLVQ
     LYGVCLEQAP ICLVFEFMEH GCLSDYLRTQ RGLFAAETLL GMCLDVCEGM AYLEEACVIH
     RDLAARNCLV GENQVIKVSD FGMTRFVLDD QYTSSTGTKF PVKWASPEVF SFSRYSSKSD
     VWSFGVLMWE VFSEGKIPYE NRSNSEVVED ISTGFRLYKP RLASTHVYQI MNHCWKERPE
     DRPAFSRLLR QLAEIAESGL
//
